Have you ever looked at your investment portfolio – or even just your personal budget – and felt like you were trying to catch a moving train? The market moves fast, and lately, the pharmaceutical sector has been sprinting. If you’ve been keeping an eye on the news, you already know that Eli Lilly and Company (LLY) has been absolutely dominating financial conversations. Between a jaw-dropping financial report and game-changing clinical trial data, Eli Lilly’s New Obesity Pill is fundamentally shifting how investors and healthcare professionals view the future of metabolic medicine. When iconic companies make massive waves like this, it reminds me of other high-conviction moves in the market…